UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Health care costs of influenza-related episodes in high income countries: A systematic review

PloS one, 2018-09, Vol.13 (9), p.e0202787-e0202787

2018

Volltextzugriff (PDF)

Shortage of plasma-derived medicinal products: what is next? narrative literature review on its causes and counteracting policies in Italy

Frontiers in pharmacology, 2024-05, Vol.15, p.1375891-1375891

2024

Volltextzugriff (PDF)

Key drivers of innovativeness appraisal for medicines: the Italian experience after the adoption of the new ranking system

BMJ open, 2021-01, Vol.11 (1), p.e041259-e041259

2021

Volltextzugriff (PDF)

The economic impact of compassionate use of medicines

BMC health services research, 2021-12, Vol.21 (1), p.1303-1303, Article 1303

2021

Volltextzugriff (PDF)

CAR T-Cell Therapies in Italy: Patient Access Barriers and Recommendations for Health System Solutions

Frontiers in pharmacology, 2022-06, Vol.13, p.915342

2022

Volltextzugriff (PDF)

Price and reimbursement of medicines when new indications are approved: the results of a survey on ISPOR Italy Rome Chapter members

Global & regional health technology assessment (Online), 2023-05, Vol.10 (1), p.40-45

2023

Volltextzugriff (PDF)

Cost-effectiveness and Net Monetary Benefit of Durvalumab Consolidation Therapy Versus No Consolidation Therapy After Chemoradiotherapy in Stage III Non–small Cell Lung Cancer in the Italian National Health Service

Clinical therapeutics, 2020-05, Vol.42 (5), p.830-847

2020

Volltextzugriff (PDF)

How are health technology assessment bodies responding to the assessment challenges posed by cell and gene therapy?

BMC health services research, 2023-05, Vol.23 (1), p.484-484, Article 484

2023

Volltextzugriff (PDF)

Price and reimbursement of advanced therapeutic medicinal products in Europe: are assessment and appraisal diverging from expert recommendations?

Journal of pharmaceutical policy and practice, 2021-03, Vol.14 (1), p.30, Article 30

2021

Volltextzugriff (PDF)

Early access programs for medicines: a reform proposal for the Italian National Health Service

Global & regional health technology assessment (Online), 2024-06, Vol.11 (1)

2024

Volltextzugriff (PDF)

Assessment of innovativeness, and price and reimbursement negotiation of medicines: recommendations of an expert panel

Global & regional health technology assessment (Online), 2024-07, Vol.11 (1), p.169-174

2024

Volltextzugriff (PDF)

The economic impact of 14 compassionate use programs for medicines in Italy, in the perspective of the National Health Service

Global & regional health technology assessment (Online), 2024-05, Vol.11 (1), p.115-123

2024

Volltextzugriff (PDF)

Mesenchymal stem cell secretome and extracellular vesicles for neurodegenerative diseases: Risk-benefit profile and next steps for the market access

Bioactive materials, 2023-11, Vol.29, p.16-35

2023

Volltextzugriff (PDF)

Unmet need: definitions, literature evidence and implications for HTA

Global & regional health technology assessment (Online), 2023-10, Vol.10 (1), p.70-78

2023

Volltextzugriff (PDF)

Variables affecting pricing of orphan drugs: the Italian case

Orphanet journal of rare diseases, 2021-10, Vol.16 (1), p.1-439, Article 439

2021

Volltextzugriff (PDF)

Early access programs for medicines: comparative analysis among France, Italy, Spain, and UK and focus on the Italian case

Journal of pharmaceutical policy and practice, 2023-05, Vol.16 (1), p.67-67

2023

Volltextzugriff (PDF)

Cost of implementing CAR-T activity and managing CAR-T patients: an exploratory study

BMC health services research, 2024-01, Vol.24 (1), p.121-11, Article 121

2024

Volltextzugriff (PDF)

Budget impact analysis of rituximab biosimilar in Italy from the hospital and payer perspectives

Global & regional health technology assessment (Online), 2018-06, Vol.2018, p.228424031878428

2018

Volltextzugriff (PDF)

The costs incurred by patients to get eligibility to PCSK9 treatment and one-year follow-up: the results of the PRIOR Study

Global & regional health technology assessment (Online), 2022-07, Vol.9 (1), p.73-81

2022

Volltextzugriff (PDF)

The role of health technology assessment bodies in shaping drug development

Drug design, development and therapy, 2014-01, Vol.8 (default), p.2273-2281

2014

Volltextzugriff (PDF)

The Economic Impact of a Switch From Prescription-Only to Non-prescription Drugs in Italy

Frontiers in pharmacology, 2018-10, Vol.9, p.1069-1069

2018

Volltextzugriff (PDF)

Content validity of the EQ-HWB and EQ-HWB-S in a sample of Italian patients, informal caregivers and members of the general public

Journal of patient-reported outcomes, 2024-03, Vol.8 (1), p.36-14, Article 36

2024

Volltextzugriff (PDF)

Regional Formularies in Italy: current state and future perspectives

Global & regional health technology assessment (Online), 2024-03, Vol.11 (1), p.68-74

2024

Volltextzugriff (PDF)

The value of obinutuzumab for untreated advanced Follicular Lymphoma: an assessment based on Multicriteria Decision Analysis (MCDA)

Aboutopen, 2019-11, Vol.6 (1), p.78-85

2019

Volltextzugriff (PDF)

Corrigendum: The Economic Impact of a Switch From Prescription-Only to Non-prescription Drugs in Italy

Frontiers in pharmacology, 2019-03, Vol.10, p.129-129

2019

Volltextzugriff (PDF)

1 – 25 von 157

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(147)
Mit Volltextzugriff
(143)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Health care costs of influenza-related episodes in high income countries: A systematic review

Shortage of plasma-derived medicinal products: what is next? narrative literature review on its causes and counteracting policies in Italy

Key drivers of innovativeness appraisal for medicines: the Italian experience after the adoption of the new ranking system

The economic impact of compassionate use of medicines

CAR T-Cell Therapies in Italy: Patient Access Barriers and Recommendations for Health System Solutions

Price and reimbursement of medicines when new indications are approved: the results of a survey on ISPOR Italy Rome Chapter members

Cost-effectiveness and Net Monetary Benefit of Durvalumab Consolidation Therapy Versus No Consolidation Therapy After Chemoradiotherapy in Stage III Non–small Cell Lung Cancer in the Italian National Health Service

How are health technology assessment bodies responding to the assessment challenges posed by cell and gene therapy?

Price and reimbursement of advanced therapeutic medicinal products in Europe: are assessment and appraisal diverging from expert recommendations?

Early access programs for medicines: a reform proposal for the Italian National Health Service

Assessment of innovativeness, and price and reimbursement negotiation of medicines: recommendations of an expert panel

The economic impact of 14 compassionate use programs for medicines in Italy, in the perspective of the National Health Service

Mesenchymal stem cell secretome and extracellular vesicles for neurodegenerative diseases: Risk-benefit profile and next steps for the market access

Unmet need: definitions, literature evidence and implications for HTA

Variables affecting pricing of orphan drugs: the Italian case

Early access programs for medicines: comparative analysis among France, Italy, Spain, and UK and focus on the Italian case

Cost of implementing CAR-T activity and managing CAR-T patients: an exploratory study

Budget impact analysis of rituximab biosimilar in Italy from the hospital and payer perspectives

The costs incurred by patients to get eligibility to PCSK9 treatment and one-year follow-up: the results of the PRIOR Study

The role of health technology assessment bodies in shaping drug development

The Economic Impact of a Switch From Prescription-Only to Non-prescription Drugs in Italy

Content validity of the EQ-HWB and EQ-HWB-S in a sample of Italian patients, informal caregivers and members of the general public

Regional Formularies in Italy: current state and future perspectives

The value of obinutuzumab for untreated advanced Follicular Lymphoma: an assessment based on Multicriteria Decision Analysis (MCDA)

Corrigendum: The Economic Impact of a Switch From Prescription-Only to Non-prescription Drugs in Italy

Suchergebnisse filtern